Scientific deep-dive

GLP-1s and Atrial Fibrillation: Reading a 42% Headline

A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·3 citations

A 2024 meta-analysis reported that semaglutide cut the risk of new atrial fibrillation by 42%.[1] That is a striking number and it has traveled a long way. Before it travels any further, know what kind of number it is. It was assembled from ten trials, and none of them set out to study atrial fibrillation at all.

What was actually pooled

The analysis brought together ten randomized trials covering 12,651 patients, 7,285 of them on semaglutide and 5,366 on placebo, in populations at high cardiovascular risk and largely with type 2 diabetes. Pooled with a random-effects model, the relative risk of incident atrial fibrillation was 0.58, with a 95% confidence interval of 0.40 to 0.85 and no measurable heterogeneity between studies.[1]

The consistency is the impressive part. An I² of zero means the ten trials pointed the same way, with no single outlier dragging the average. Subgroup analysis found no difference between oral and injected semaglutide, and meta-regression found no influence from the proportion of patients with diabetes or from body mass index.[1]

None of those ten trials was designed to measure atrial fibrillation. They were cardiovascular outcome and glycemic trials, and AF appears in them as reported adverse-event data rather than as an adjudicated endpoint someone was actively hunting for. Adverse-event counting is systematically less reliable than adjudicated outcomes: a rhythm that never caused symptoms may simply never have been recorded. This is a hypothesis worth a dedicated trial, not a demonstrated benefit.

42% of what?

A relative risk needs a partner. A 42% reduction tells you how much smaller the risk became; it says nothing about how large the risk was to begin with. Cut a small number by 42% and you have prevented very few events.

The published summary reports the relative risk without the absolute event counts, so we cannot give the second number, and we will not estimate one. The general shape is still clear. Atrial fibrillation was an uncommon event in these populations over these timeframes, so the absolute difference behind that 42% is small.

The 42% says how much smaller the risk became, not how large it was to begin with.

Why 'semaglutide' and not 'GLP-1 drugs'

The authors draw this distinction carefully. When they wrote in 2024, the class as a whole was regarded as neutral on arrhythmia risk; what their data suggested is a possible benefit specific to semaglutide.[1]

Update, September 11, 2026. Newer pooled evidence points to a class effect rather than a semaglutide-only one. A 2026 meta-analysis of 24 obesity trials, covering 40,694 people, found GLP-1 drugs and their dual-agonist cousins lowered new atrial fibrillation by 18%, with no difference between individual drugs.[2] Tirzepatide is the open question: a September 2026 analysis of its obesity trials found no significant change in atrial fibrillation, and a higher rate of arrhythmias of any kind, based on few events.[3]

Drug-specific effects inside a drug class are interesting for two opposite reasons. Sometimes they are real pharmacology, because molecules in a class do differ. Sometimes they are an artifact of which trials happened to be run, in which populations, with which reporting practices. A finding that appears in one member of a class and not the others deserves more scrutiny than a class-wide one, not less.

There is a plausible mechanism, which is not the same as evidence: obesity, sleep apnea and hypertension all drive atrial fibrillation, and these drugs improve all three. If the effect is real, it may be largely downstream of weight rather than anything specific to the heart. Our sleep apnea article covers the one of those three with a dedicated trial behind it.

What to do with this

  • It is not a reason to start one of these drugs. No GLP-1 is approved for preventing atrial fibrillation, and evidence assembled from adverse-event reporting would not support that even if it were larger.
  • It says little about people who already have AF. These trials counted new cases; the direction of the data is not toward harm, but what happens to an existing arrhythmia is a separate question.
  • It does not replace anything. Anticoagulation decisions, rate and rhythm control belong to cardiology and are unaffected by this. If you take a blood thinner, what the labels say about combining it with a GLP-1 is in blood thinners and a GLP-1.
  • Palpitations are still worth reporting. Heart rate increases are a known effect of this drug class and appear in the labels, as why a GLP-1 raises your heart rate explains; a new irregular heartbeat is a reason to call your doctor.

This is a promising, internally consistent signal from data collected for other purposes. It is a good reason to run the trial that would answer the question properly, but not yet a reason to change what anybody does.

Frequently Asked Questions

A 2024 meta-analysis of ten randomized trials in 12,651 patients found a pooled relative risk of 0.58 (a 42% reduction), with no heterogeneity between studies. But none of those trials was designed to measure atrial fibrillation; it appears as reported adverse-event data rather than an adjudicated endpoint, so this is a hypothesis worth testing rather than a demonstrated benefit.
The published summary gives the relative risk without absolute event counts, so it cannot be stated, and we will not estimate it. Atrial fibrillation was uncommon in these populations over these timeframes, so the absolute difference behind the 42% is small.
The picture has changed since this study. A 2026 pooling of 24 obesity trials found a reduction in new atrial fibrillation across the class, with no difference between drugs. For tirzepatide specifically, a September 2026 analysis found no significant change in atrial fibrillation but more arrhythmias of any kind, based on few events, so that question is still open.
That is a question for your cardiologist, who knows your rhythm history and your other medications. These trials counted new cases of atrial fibrillation, not what happened to people who already had it. Nothing here changes anticoagulation, rate or rhythm control decisions.
There is a plausible indirect route: obesity, sleep apnea and hypertension all drive atrial fibrillation, and these drugs improve all three. If the effect is real it may be largely downstream of weight loss rather than anything specific to cardiac tissue. A plausible mechanism is not evidence, though.

References

  1. 1.Saglietto A, Falasconi G, Penela D, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis European Journal of Clinical Investigation. 2024. PMID: 39058274.
  2. 2.Karakasis P, Vlachos K, Antoniadis AP, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials Metabolism. 2026. PMID: 41349790.
  3. 3.Mansouri ES, Queiroga F, Barbosa LM, et al. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials Journal of the American Heart Association. 2026. PMID: 42714458.

Two Studies, One Comparison, Two Answers

One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.

6 min read

GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop

On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.

8 min read

Semaglutide and Days Spent in Hospital

A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.

5 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

A Biomarker Is Not an Outcome

Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.

8 min read

A Benefit Nobody Observed

A cardiology journal reports GLP-1 therapy could cut ten-year cardiovascular risk by 22% in people who have never had heart disease. Nobody in the study took the drug.

6 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →